French National Observatory of Patients With Thymic Epithelial Tumor
NCT ID: NCT02724696
Last Updated: 2023-05-24
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
RECRUITING
Total Enrollment
3262 participants
Study Classification
OBSERVATIONAL
Study Start Date
2012-01-31
Study Completion Date
2025-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
RYTHMIC (Réseau tumeurs THYMiques et Cancer) is a French nationwide network for TET with the objective of territorial coverage by regional expert centers and systematic discussion of patients management at national tumor board.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Transplantation After Complete Response In Patients With T-cell Lymphoma
NCT05444712
Peripheral T Cell Lymphoma
RECRUITING
NA
Randomized, Multicenter, Phase III Trial to Assess Conformal Post-operative Radiotherapy vs. Surveillance After Complete Resection of Stage II/III Thymoma (RADIO-RYTHMIC-01)
NCT04731610
Thymoma Malignant Recurrent
RECRUITING
NA
A Study of YM155 Plus Rituximab in Subjects With Non-Hodgkin's Lymphoma Who Have Received Prior Treatment
NCT01007292
Non-Hodgkin's Lymphoma
COMPLETED
PHASE2
Indication to Transplant Patients With High Risk B Cells Lymphoma in Metabolic Complete Remission?
NCT03681938
Lymphoma, B-Cell
UNKNOWN
A Phase II Study of Rituximab Combined With CHOP in T-cell Angio-immunoblastic Lymphoma
NCT00169156
Untreated T-cell Angioimmunoblastic Lymphoma
COMPLETED
PHASE2
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
RYTHMIC (Réseau tumeurs THYMiques et Cancer) is a nationwide network for TET appointed in 2012 by the French National Cancer Institute. The objectives of the network are management of clinical tumor boards and central pathologic review of all cases. RYTHMIC Tumor Board is based on initial histopathological diagnosis.
RYTHMIC is a comprehensive tool for research:
* to improve the management of patients
* to monitor dedicated actions
* to screen patients for future translational and clinical trials
RYTHMIC is a comprehensive tool for research:
* to improve the management of patients
* to monitor dedicated actions
* to screen patients for future translational and clinical trials
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Thymic Epithelial Tumor
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Observational Model Type
COHORT
Study Time Perspective
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* patient with Thymic Epithelial Tumors
Exclusion Criteria
* histology other than Thymic Epithelial Tumors
Minimum Eligible Age
18 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Intergroupe Francophone de Cancerologie Thoracique
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Benjamin BESSE, Dr
Role: PRINCIPAL_INVESTIGATOR
Villejuif - Gustave Roussy
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Paris - Institut Curie
Paris, , France
Site Status
RECRUITING
Villejuif - Institut Gustave Roussy
Villejuif, , France
Site Status
RECRUITING
Countries
Review the countries where the study has at least one active or historical site.
France
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Chalabreysse L, Thomas De Montpreville V, De Muret A, Hofman V, Lantuejoul S, Parrens M, Payan MJ, Rouquette I, Secq V, Girard N, Marx A, Besse B, Molina TJ. [Rythmic-pathology: the French national pathology network for thymic epithelial tumours]. Ann Pathol. 2014 Feb;34(1):87-91. doi: 10.1016/j.annpat.2014.01.010. Epub 2014 Feb 21. French.
Reference Type
RESULT
Hadoux J, Girard N, Besse B. [Thymic epithelial neoplasms: updates on diagnosis, staging, biology and management in France]. Bull Cancer. 2012 Nov;99(11):1045-55. doi: 10.1684/bdc.2012.1659. French.
Reference Type
RESULT
Thomas de Montpreville V, Quilhot P, Chalabreysse L, De Muret A, Hofman V, Lantuejoul S, Parrens M, Payan MJ, Rouquette I, Secq V, Girard N, Besse B, Marx A, Molina TJ. Glut-1 intensity and pattern of expression in thymic epithelial tumors are predictive of WHO subtypes. Pathol Res Pract. 2015 Dec;211(12):996-1002. doi: 10.1016/j.prp.2015.10.005. Epub 2015 Oct 19.
Reference Type
RESULT
Remon J, Girard N, Mazieres J, Dansin E, Pichon E, Greillier L, Dubos C, Lindsay CR, Besse B. Sunitinib in patients with advanced thymic malignancies: Cohort from the French RYTHMIC network. Lung Cancer. 2016 Jul;97:99-104. doi: 10.1016/j.lungcan.2016.04.024. Epub 2016 May 3.
Reference Type
RESULT
Merveilleux du Vignaux C, Dansin E, Mhanna L, Greillier L, Pichon E, Kerjouan M, Clement-Duchene C, Mennecier B, Westeel V, Robert M, Quantin X, Zalcman G, Thiberville L, Lena H, Molina T, Calcagno F, Fournel P, Mazieres J, Besse B, Girard N. Systemic Therapy in Advanced Thymic Epithelial Tumors: Insights from the RYTHMIC Prospective Cohort. J Thorac Oncol. 2018 Nov;13(11):1762-1770. doi: 10.1016/j.jtho.2018.08.005. Epub 2018 Aug 21.
Reference Type
RESULT
Basse C, Thureau S, Bota S, Dansin E, Thomas PA, Pichon E, Lena H, Massabeau C, Clement-Duchene C, Massard G, Westeel V, Quantin X, Oulkhouir Y, Danhier S, Lerouge D, Tanguy R, Thillays F, Le Pechoux C, Dubray B, Thiberville L, Besse B, Girard N. Multidisciplinary Tumor Board Decision Making for Postoperative Radiotherapy in Thymic Epithelial Tumors: Insights from the RYTHMIC Prospective Cohort. J Thorac Oncol. 2017 Nov;12(11):1715-1722. doi: 10.1016/j.jtho.2017.07.023. Epub 2017 Jul 31.
Reference Type
RESULT
Drevet G, Collaud S, Tronc F, Girard N, Maury JM. Optimal management of thymic malignancies: current perspectives. Cancer Manag Res. 2019 Jul 22;11:6803-6814. doi: 10.2147/CMAR.S171683. eCollection 2019.
Reference Type
RESULT
Remon J, Girard N, Mazieres J, Dansin E, Pichon E, Greillier L, Dubos C, Lindsay CR, Besse B. Erratum to "Sunitinib in patients with advanced thymic malignancies: cohort from the French RYTHMIC network" [Lung Cancer, 97 (July 2016), 99-104]. Lung Cancer. 2016 Nov;101:146. doi: 10.1016/j.lungcan.2016.09.014. Epub 2016 Oct 6. No abstract available.
Reference Type
RESULT
Rouquette I, Taranchon-Clermont E, Gilhodes J, Bluthgen MV, Perallon R, Chalabreysse L, De Muret A, Hofman V, Marx A, Parrens M, Secq V, Thomas de Montpreville V, Galateau-Salle F, Brousset P, Milia J, Girard N, Besse B, Molina TJ, Mazieres J. Immune biomarkers in thymic epithelial tumors: expression patterns, prognostic value and comparison of diagnostic tests for PD-L1. Biomark Res. 2019 Dec 4;7:28. doi: 10.1186/s40364-019-0177-8. eCollection 2019.
Reference Type
RESULT
Girard N, Merveilleux Du Vignaux C, Molina T, Besse B, Rythmic R. [Thymic tumors]. Rev Prat. 2017 Apr;67(4):430-434. French.
Reference Type
RESULT
Chalabreysse L, Dubois R, Hofman V, Le Naoures C, Mansuet-Lupo A, de Montpreville VT, De Muret A, Parrens M, Piton N, Rouquette I, Secq V, Singeorzan C, Marx A, Girard N, Besse B, Molina TJ. [Thymoma and squamous thymic carcinoma diagnosis; experience from the RYTHMIC network]. Ann Pathol. 2021 Apr;41(2):154-165. doi: 10.1016/j.annpat.2020.11.002. Epub 2020 Dec 10. French.
Reference Type
RESULT
Molina TJ, Bluthgen MV, Chalabreysse L, de Montpreville VT, de Muret A, Dubois R, Hofman V, Lantuejoul S, le Naoures C, Mansuet-Lupo A, Parrens M, Piton N, Rouquette I, Secq V, Girard N, Marx A, Besse B. Impact of expert pathologic review of thymic epithelial tumours on diagnosis and management in a real-life setting: A RYTHMIC study. Eur J Cancer. 2021 Jan;143:158-167. doi: 10.1016/j.ejca.2020.11.011. Epub 2020 Dec 11.
Reference Type
RESULT
Petat A, Dansin E, Calcagno F, Greillier L, Pichon E, Kerjouan M, Clement-Duchene C, Mennecier B, Westeel V, Thillays F, Quantin X, Oulkhouir Y, Thiberville L, Ricordel C, Thomas De Montpreville V, Chalabreysse L, Hofman V, Molina T, Fournel P, Bigay Game L, Besse B, Girard N. Treatment strategies for thymic carcinoma in a real-life setting. Insights from the RYTHMIC network. Eur J Cancer. 2022 Feb;162:118-127. doi: 10.1016/j.ejca.2021.11.028. Epub 2021 Dec 26.
Reference Type
RESULT
Thomas de Montpreville V, Mansuet-Lupo A, Le Naoures C, Chalabreysse L, De Muret A, Hofman V, Rouquette I, Piton N, Dubois R, Benitez JC, Girard N, Besse B, Marx A, Molina TJ. Micronodular thymic carcinoma with lymphoid hyperplasia: relevance of immunohistochemistry with a small panel of antibodies for diagnosis-a RYTHMIC study. Virchows Arch. 2021 Oct;479(4):741-746. doi: 10.1007/s00428-021-03044-2. Epub 2021 Feb 24.
Reference Type
RESULT
Benitez JC, Boucher ME, Dansin E, Kerjouan M, Bigay-Game L, Pichon E, Thillays F, Falcoz PE, Lyubimova S, Oulkhouir Y, Calcagno F, Thiberville L, Clement-Duchene C, Westeel V, Missy P, Thomas PA, Maury JM, Molina T, Girard N, Besse B. Central Nervous System Metastases in Thymic Epithelial Tumors: A Brief Report of Real-World Insight From RYTHMIC. J Thorac Oncol. 2021 Dec;16(12):2144-2149. doi: 10.1016/j.jtho.2021.08.008. Epub 2021 Aug 26.
Reference Type
RESULT
Basse C, Botticella A, Molina TJ, Falcoz PE, Oulkhouir Y, Kerjouan M, Pichon E, Westeel V, Thiberville L, Quantin X, Clement-Duchene C, Khalifa J, Tinier FL, Ginoux M, Thillays F, Mordant P, Besse B, Thomas PA, Pechoux CL, Girard N. RADIORYTHMIC: Phase III, Opened, Randomized Study of Postoperative Radiotherapy Versus Surveillance in Stage IIb/III of Masaoka Koga Thymoma after Complete Surgical Resection. Clin Lung Cancer. 2021 Sep;22(5):469-472. doi: 10.1016/j.cllc.2021.01.020. Epub 2021 Feb 4.
Reference Type
RESULT
Noel N, Le Roy A, Hot A, Saadoun D, Lazaro E, Levesque H, Le Gouellec N, Meaux-Ruault N, Nguyen T, Costedoat-Chalumeau N, Amieux B, Fontana A, De Gennes C, Fulpin J, Thomas PA, Bluthgen MV, Besse B, Lambotte O. Systemic lupus erythematosus associated with thymoma: A fifteen-year observational study in France. Autoimmun Rev. 2020 Mar;19(3):102464. doi: 10.1016/j.autrev.2020.102464. Epub 2020 Jan 7.
Reference Type
RESULT
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IFCT-1104 RYTHMIC
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Retrospective Analysis of Rituximab-containing Immunochemotherapy for Burkitt's or Burkitt-like Lymphoma in Adults
NCT01809600
COMPLETED
Different Molecular Subtypes of Peripheral T-cell Lymphoma, a Real-world Registry Study. (TRUST)
NCT05934864
RECRUITING
Radiomics and Metabolomics in the Follow-up of CAR T-cells for Refractory or Relapsed Non-Hodgkin's Lymphoma
NCT05422521
RECRUITING
NA
Clinico-biological Characterization and Survival of Patients With Adult T-cell Leukemia / Lymphoma (ATL) and Patients Chronically Infected With the HTLV-1 Virus (HTLV-OBS)
NCT05237245
RECRUITING
Institut Paoli Calmettes Lymphoma Database
NCT02869542
RECRUITING
Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment Registry
NCT01110733
COMPLETED
Immunotherapy in Lymphoma
NCT06796517
RECRUITING
Registry of Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia
NCT05832125
UNKNOWN
Application of Telemedicine to the Management of Aggressive Lymphomas
NCT03336138
COMPLETED
NA
Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK-cell Neoplasms
NCT03493451
COMPLETED
PHASE2
Immunological Repertoire in Patients With Lymphoma and Chronic Lymphocytic Leukemia
NCT02520895
COMPLETED
Efficacy of Patient Management for Lymphoma Diagnosed at Nimes University Hospital From 1999 to 2018. DVR-Lym-Nim
NCT04947618
RECRUITING
Efficacy Study of Rituximab After ASCT in High-Risk Diffuse Large B-Cell Lymphoma
NCT00169169
TERMINATED
PHASE3
TREatment of degeNerative and Neoplastic Diseases With Rituximab
NCT01277172
UNKNOWN
PHASE2/PHASE3
Circulating Tumor DNA Sequencing in Patients With Peripheral T-cell Lymphomas
NCT06089941
ACTIVE_NOT_RECRUITING
T-Cell Project: Prospective Collection of Data in Patients With Peripheral T-Cell Lymphoma
NCT01142674
COMPLETED
Tafasitamab and Lenalidomide as First Salvage Therapy for Residual Large B Cell Lym
NCT06760156
RECRUITING
PHASE2
Electronic MonitorIng of Events for dIffuse Large b Cell LYmphoma
NCT05298293
NOT_YET_RECRUITING
NA
Assessment of Blood Biomarkers by DNA Microarrays in Patients With Aggressive Lymphoma BMS_LyTrans
NCT01287923
COMPLETED
Treatment of Localized Low Grade Lymphomas
NCT00536458
COMPLETED
PHASE3
A Study of MabThera/Rituxan (Rituximab) in Patients With Non-Bulky Follicular Non-Hodgkin's Lymphoma
NCT01392716
COMPLETED
PHASE2
Loncastuximab Tesirine and Rituximab as Bridging Therapy Before Standard-of-care CAR-T Therapy in Patients With Large B-cell Lymphoma (CORAL)
NCT06788964
RECRUITING
PHASE2
Study of the Biological Mechanisms Associated With the Immunogenicity in Anaplastic Large Cell Lymphoma ( ALCL ) ALK +
NCT02902874
COMPLETED
NA
Exosomes and Immunotherapy in Non-Hodgkin B-cell Lymphomas
NCT03985696
UNKNOWN
NA